Detalhe da pesquisa
1.
Glecaprevir-Pibrentasvir for 8 or 12 Weeks in HCV Genotype 1 or 3 Infection.
N Engl J Med
; 378(4): 354-369, 2018 01 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-29365309
2.
Drug-Drug Interactions of Glecaprevir and Pibrentasvir Coadministered With Human Immunodeficiency Virus Antiretrovirals.
J Infect Dis
; 221(2): 223-231, 2020 01 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-31504702
3.
Long-term safety and efficacy results in hepatitis C virus genotype 1-infected patients receiving ombitasvir/paritaprevir/ritonavir + dasabuvir ± ribavirin in the TOPAZ-I and TOPAZ-II trials.
J Viral Hepat
; 27(5): 497-504, 2020 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-31954087
4.
Safety and Pharmacokinetics of Glecaprevir/Pibrentasvir in Adults With Chronic Genotype 1-6 Hepatitis C Virus Infections and Compensated Liver Disease.
Clin Infect Dis
; 69(10): 1657-1664, 2019 10 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-30923816
5.
Glecaprevir/Pibrentasvir in patients with chronic HCV genotype 3 infection: An integrated phase 2/3 analysis.
J Viral Hepat
; 26(3): 337-349, 2019 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-30421537
6.
Glecaprevir/Pibrentasvir in patients with hepatitis C virus genotype 1 or 4 and past direct-acting antiviral treatment failure.
Hepatology
; 67(4): 1253-1260, 2018 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-29152781
7.
Glecaprevir and pibrentasvir for 12 weeks for hepatitis C virus genotype 1 infection and prior direct-acting antiviral treatment.
Hepatology
; 66(2): 389-397, 2017 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-28128852
8.
Glecaprevir and pibrentasvir yield high response rates in patients with HCV genotype 1-6 without cirrhosis.
J Hepatol
; 67(2): 263-271, 2017 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-28412293
9.
No Clinically Relevant Drug-Drug Interactions between Methadone or Buprenorphine-Naloxone and Antiviral Combination Glecaprevir and Pibrentasvir.
Antimicrob Agents Chemother
; 61(10)2017 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-28807904
10.
High Efficacy of ABT-493 and ABT-530 Treatment in Patients With HCV Genotype 1 or 3 Infection and Compensated Cirrhosis.
Gastroenterology
; 151(4): 651-659.e1, 2016 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-27456384
11.
Assessment of effect of CYP3A inhibition, CYP induction, OATP1B inhibition, and high-fat meal on pharmacokinetics of the JAK1 inhibitor upadacitinib.
Br J Clin Pharmacol
; 83(10): 2242-2248, 2017 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-28503781
12.
High antiviral activity of NS5A inhibitor ABT-530 with paritaprevir/ritonavir and ribavirin against hepatitis C virus genotype 3 infection.
Liver Int
; 36(8): 1125-32, 2016 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-26778412
13.
Potent Antiviral Activities of the Direct-Acting Antivirals ABT-493 and ABT-530 with Three-Day Monotherapy for Hepatitis C Virus Genotype 1 Infection.
Antimicrob Agents Chemother
; 60(3): 1546-55, 2015 Dec 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-26711747
14.
Pharmacokinetics, Tolerability, and Safety of Glecaprevir/Pibrentasvir Co-formulated Bilayer Tablet Following Repeated Administration in Healthy Chinese Adults.
Clin Pharmacol Drug Dev
; 12(10): 945-955, 2023 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-37661787
15.
Efficacy and Safety of Glecaprevir/Pibrentasvir in Korean Patients with Chronic Hepatitis C: A Pooled Analysis of Five Phase II/III Trials.
Gut Liver
; 15(6): 895-903, 2021 11 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-34053916
16.
Glecaprevir-pibrentasvir to treat chronic hepatitis C virus infection in Asia: two multicentre, phase 3 studies- a randomised, double-blind study (VOYAGE-1) and an open-label, single-arm study (VOYAGE-2).
Lancet Gastroenterol Hepatol
; 5(9): 839-849, 2020 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-32682494
17.
Drug-Drug Interactions of Tacrolimus or Cyclosporine With Glecaprevir and Pibrentasvir in Healthy Subjects.
Clin Pharmacol Drug Dev
; 8(6): 779-789, 2019 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-30861340
18.
Safety and efficacy of glecaprevir/pibrentasvir for the treatment of chronic hepatitis C in patients aged 65 years or older.
PLoS One
; 14(1): e0208506, 2019.
Artigo
em Inglês
| MEDLINE | ID: mdl-30601818
19.
Glecaprevir/pibrentasvir in patients with chronic HCV and recent drug use: An integrated analysis of 7 phase III studies.
Drug Alcohol Depend
; 194: 487-494, 2019 01 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30529905
20.
Pharmacokinetic Interactions and Safety of Coadministration of Glecaprevir and Pibrentasvir in Healthy Volunteers.
Eur J Drug Metab Pharmacokinet
; 43(1): 81-90, 2018 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-28688001